Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Muscle Nerve. 2010 Aug;42(2):157–164. doi: 10.1002/mus.21661

Table 1.

Frequency of Neuropathy Endpoint Abnormalities of Individual Patients in the Cl vs NPhys Trial*

Patient Age Gender Clinical Neurologic Exam1 NC2
Signs
(no. of
24 eval.)		 Symptoms
(no. of 24
eval.)		 Diagnosis
(no. of 24
eval.)		 PMCV Σ 5 NC
nds
1 68 F 16 1 8 0 of 2 0 of 2
2 67 F 0 2 0 0 of 2 0 of 2
3 67 M 19 1 5 0 of 2 0 of 2
4 63 M 18 0 7 0 of 2 0 of 2
5 68 M 23 0 13 0 of 2 0 of 2
6 62 M 22 12 11 0 of 2 0 of 2
7 62 M 24 0 18 0 of 2 0 of 2
8 73 M 22 16 7 0 of 2
9 67 M 22 0 15 2 of 2 0 of 2
10 56 F 15 3 3 0 of 2 0 of 2
11 53 M 22 19 16 0 of 2 0 of 2
12 49 M 17 0 12 2 of 2 0 of 2
13 50 F 15 2 6 2 of 2 2 of 2
14 65 M 23 1 16 2 of 2 2 of 3
15 72 F 23 0 14 2 of 2 2 of 2
16 73 M 24 3 21 2 of 2 2 of 2
17 55 M 24 14 19 0 of 2 2 of 2
18 65 M 24 23 23 0 of 2 2 of 2
19 38 F 6 0 3 2 of 2 2 of 2
20 66 M 24 23 20 2 of 2 2 of 2
21 67 M 23 22 23 2 of 2 2 of 3
22 73 F 24 22 24 2 of 2 2 of 2
23 58 M 24 21 24 2 of 2 2 of 2
24 63 M 24 10 22 2 of 2 2 of 2
N (%) abn. 18 (75.0) 6 (25.0) 9 (37.5) 12 (50.0) 12 (50.0)
*

The full table with inclusion of quantitative sensation and autonomic tests and composite scores is provided as supplementary material.

1

Signs, symptoms and diagnosis confirmed when ≥ 75% of 12 study physicians diagnosed them on 2 occasions or if ≥ 75% of 24 examinations were so diagnosed. Shaded boxes indicate 75% diagnostic levels of abnormality.

2

For all clinical neurophysiologic test results, abnormality was ≥ 95th or ≤ 5th percentile based on normative values obtained from RDNS-HS cohort studies56. When composite scores were used, normal deviates values from percentiles, always in the upper tail of the normal distribution, were added and divided by the number of measured variables (e.g., when CMAP is 0, velocity and distal latency cannot be evaluated) and this quotient is then multiplied by the number of measurable variables in the composite score. The 95th percentile lines of the composite scores were estimated in the RDNS-HS cohort56.

A column for patients with both signs and symptoms is not provided since it would be identical to the column for symptoms.